Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies and Vaccines
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Info For
    • Manuscript Submission
      • 1-Minute Consult
      • Commentary
      • Current Drug Therapy
      • Editorial
      • Guidelines to Practice
      • Interpreting Key Trials
      • Letter to the Editor
      • Review
      • Smart Testing
      • Symptoms to Diagnosis
      • The Clinical Picture
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • Multimedia
    • Sponsored Videos
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies and Vaccines
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • Multimedia
    • Sponsored Videos
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
Interpreting Key Trials

Renal denervation: What happened, and why?

Mehdi H. Shishehbor, DO, MPH, PhD, Tarek A. Hammad, MD and George Thomas, MD, MPH
Cleveland Clinic Journal of Medicine September 2017, 84 (9) 681-686; DOI: https://doi.org/10.3949/ccjm.84a.14129
Mehdi H. Shishehbor
Professor of Medicine, Case Western Reserve University, Cleveland, OH
Co-Chair, Harring Heart and Vascular Institute
Director, Cardiovascular Interventional Center
CoDirector, Vascular Center, University Hospitals of Cleveland, OH
Site Principal Investigator, SYMPLICITY HTN-3 trial
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shishem@gmail.com
Tarek A. Hammad
Department of Medicine, Division of Cardiology, The University of Texas Health Center at San Antonio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Thomas
Director, Center for Blood Pressure Disorders, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic
Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Investigator, SYMPLICITY HTN-3 trial
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Despite promising results in initial trials, renal denervation failed to achieve its efficacy end points as a treatment for resistant hypertension in the SYMPLICITY HTN-3 trial, the largest trial of this treatment to date (N Engl J Med 2014; 370:1393-1401). Is renal denervation dead, or will future trials and newer technology revive it?

  • Copyright © 2017 The Cleveland Clinic Foundation. All Rights Reserved.
View Full Text

REFERENCES

  1. ↵
    1. Bhatt DL,
    2. Kandzari DE,
    3. O’Neill WW,
    4. et al.
    5. for the SYMPLICITY HTN-3 Investigators
    . A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393–1401.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Symplicity HTN-2 Investigators
    2. Esler MD,
    3. Krum H,
    4. Sobotka PA,
    5. Schlaich MP,
    6. Schmieder RE,
    7. Bohm M
    . Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010; 376:19031909.
    OpenUrl
  3. ↵
    1. Bunte MC,
    2. Infante de Oliveira E,
    3. Shishehbor MH
    . Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv 2013; 6:1–9.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Thomas G,
    2. Shishehbor MH,
    3. Bravo EL,
    4. Nally JV
    . Renal denervation to treat resistant hypertension: guarded optimism. Cleve Clin J Med 2012; 79:501–510.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Shishehbor MH,
    2. Bunte MC
    . Anatomical exclusion for renal denervation: are we putting the cart before the horse? JACC Cardiovasc Interv 2014; 7:193–194.
    OpenUrlFREE Full Text
  6. ↵
    1. Bhatt DL,
    2. Bakris GL
    . The promise of renal denervation. Cleve Clin J Med 2012; 79:498–500.
    OpenUrlFREE Full Text
  7. ↵
    1. Bunte MC
    . Renal sympathetic denervation for refractory hypertension. Lancet 2011; 377:1074; author reply 1075.
    OpenUrlPubMed
  8. ↵
    1. Mahfoud F,
    2. Luscher TF,
    3. Andersson B,
    4. et al
    5. European Society of Cardiology
    . Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34:2149–2157.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Schlaich MP,
    2. Schmieder RE,
    3. Bakris G,
    4. et al
    . International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol 2013; 62:2031–2045.
    OpenUrlFREE Full Text
  10. ↵
    1. Azizi M,
    2. Sapoval M,
    3. Gosse P,
    4. et al
    5. Renal Denervation for Hypertension (DENERHTN) investigators
    . Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015; 385:19571965.
    OpenUrl
  11. ↵
    1. Rosa J,
    2. Widimsky P,
    3. Tousek P,
    4. et al
    . Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension 2015; 65:407–413.
    OpenUrlCrossRef
  12. ↵
    1. Williams B,
    2. MacDonald TM,
    3. Morant S,
    4. et al
    5. British Hypertension Society’s PATHWAY Studies Group
    . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double blind, crossover trial. Lancet 2015; 386:2059–2068.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Sakakura K,
    2. Ladich E,
    3. Cheng Q,
    4. et al
    . Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol 2014; 64:635–643.
    OpenUrlFREE Full Text
  14. ↵
    1. Mahfoud F,
    2. Edelman ER,
    3. Bohm M
    . Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol 2014; 64:644–646.
    OpenUrlFREE Full Text
  15. ↵
    1. Id D,
    2. Kaltenbach B,
    3. Bertog SC,
    4. et al
    . Does the presence of accessory renal arteries affect the efficacy of renal denervation? JACC Cardiovasc Interv 2013; 6:1085–1091.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Jin Y,
    2. Jacobs L,
    3. Baelen M,
    4. et al
    5. Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (Inspired) Investigators
    . Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Press 2014; 23:138–146.
    OpenUrlCrossRefPubMed
  17. ↵
    1. ClinicalTrialsgov
    . Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN: REINFORCE). https://clinicaltrials.gov/ct2/show/NCT02392351?term=REDUCE-HTN%3A+REINFORCE&rank=1. Accessed August 3, 2017.
  18. ↵
    1. Fischell TA,
    2. Ebner A,
    3. Gallo S,
    4. et al
    . Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-inhuman experience. JACC Cardiovasc Interv 2016; 9:589–598.
    OpenUrlCrossRef
  19. ↵
    1. ClinicalTrialsgov
    . Sham controlled study of renal denervation for subjects with uncontrolled hypertension (WAVE_IV) (NCT02029885). https://clinicaltrials.gov/ct2/show/results/NCT02029885. Accessed August 3, 2017.
  20. ↵
    1. Mahfoud F,
    2. Bohm M,
    3. Azizi M,
    4. et al
    . Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 2015; 36:2219–2227.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Kandzari DE,
    2. Kario K,
    3. Mahfoud F,
    4. et al
    . The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 2016; 171:82–91.
    OpenUrlPubMed
  22. ↵
    1. ClinicalTrialsgov
    . A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN). https://clinicaltrials.gov/ct2/show/NCT02649426?term=RADIANCE&rank=3. Accessed August 3, 2017.

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Log in using your username and password

Forgot your user name or password?
PreviousNext
Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Cleveland Clinic Journal of Medicine: 84 (9)
Cleveland Clinic Journal of Medicine
Vol. 84, Issue 9
1 Sep 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Renal denervation: What happened, and why?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Renal denervation: What happened, and why?
Mehdi H. Shishehbor, Tarek A. Hammad, George Thomas
Cleveland Clinic Journal of Medicine Sep 2017, 84 (9) 681-686; DOI: 10.3949/ccjm.84a.14129

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Renal denervation: What happened, and why?
Mehdi H. Shishehbor, Tarek A. Hammad, George Thomas
Cleveland Clinic Journal of Medicine Sep 2017, 84 (9) 681-686; DOI: 10.3949/ccjm.84a.14129
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • LEAD-UP TO SYMPLICITY HTN-3
    • SYMPLICITY HTN-3 DESIGN
    • SYMPLICITY HTN-3 RESULTS
    • WHAT WENT WRONG?
    • WHAT NOW?
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Renal denervation: Are we on the right path?
  • PubMed
  • Google Scholar

Cited By...

  • Renal denervation: Are we on the right path?
  • Google Scholar

More in this TOC Section

  • Update in perioperative cardiac medicine 2021
  • The role of ISCHEMIA in stable ischemic heart disease
Show more Interpreting Key Trials

Similar Articles

Subjects

  • Vascular Medicine
  • Nephrology
  • Cardiology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit
  • Advertise Contact

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • Advertisers
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2021 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire